Ultragenyx Pharmaceutical, based in Novato, California, focuses on developing therapies for rare genetic diseases and has four approved products, including Crysvita and Mepsevii. The company went public on January 31, 2014, and employs 1,276 people.
Emil D Kakkis sold 73,434 shares of RARE on 3 March at $42.10 per share, worth a total of $3.1M. They now own 641,731 RARE shares, or a 10% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
